Johnson & Johnson MedTech | Neurovascular

J&J MedTech Neurovascular is honored to host a group of esteemed neurovascular physicians at our latest Commercial Advisory Board at our headquarters in Irvine, CA. We are grateful to this group for their valuable feedback and insights on how we can continue to improve patient outcomes and advance stroke care. #JnJMedTech #Stroke

Connecting with neurovascular 🧠 leaders at #CLOTS 2024.

#BRAINConference We are excited to meet with like-minded medical professionals at our booth to dicuss our latest solutions and upcoming innovations in neurovascular care. #JnJMedTech #Stroke

We are happy to be here at the BRAIN 🧠 Conference 2024 in London with those that are advancing our field and pushing the envelope of what is next in neurovascular care. #stroke #JNJMedTech #BRAINConference

📣 NEW DATA: Raul G. Nogueira, MD, FAHA, FSVIN | Department of Neurology recently joined us at #SVIN2024 to present data from the EXCELLENT Registry – an all-comer, prospective, international, multi center, observational registry to assess the efficacy of the EMBOTRAP™ Revascularization Device in a real-world setting, including the analysis of the composition of 546 retrieved clots. Discover the key takeaways from the EXCELLENT Registry: https://bit.ly/3ZmA2vz

The latest study in the EXCELLENT Registry assesses the efficacy of the EMBOTRAP™ Revascularization Device in a real-world setting to advance stroke care and identifies the potential impact of clot composition among patients. See the full study here: https://bit.ly/3ZmA2vz #JnJMedTech #Strokecare

Thank you to Dr. Majidi for an incredible first week using the #CEREGLIDE™ 92 Catheter System. It was amazing to see our first patient cases! Our #NTI Stroke Science was able to translate from bench to lab. Dr. Majidi shared, “CEREGLIDE™ 92 and INNERGLIDE™ 9 tracked to the M1 with ease.” A job well done all around – we are excited to continue to change the trajectory of stroke with our newly expanding CEREGLIDE™ family. Learn More: https://bit.ly/499v2xO Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions. Caution: US law restricts this device to sale by or on the order of a physician. US_CNV_ISCH_392510.1

We are excited to share our latest findings from the MEMBRANE study, a prospective, multi-center, open-label, randomized control study including 376 randomized subjects in the United States and China for the treatment of chronic subdural hematoma. Finding: MEMBRANE study shows positive primary effectiveness endpoint which demonstrates positive treatment effect of middle meningeal artery embolization with TruFill™ nBCA. #JnJMedTech #Stroke US_CNV_HEMO_393373.1

It has been non-stop at #SVIN24. Including the Women in Neurointervention breakfast, hands-on experience with our products at the Clot Workshop, Fellows Course, Posters Presentations, Innovation Suite and connecting at our booth. We are excited to showcase our product innovations in the neurovascular market. #JNJMedTech #stroke #SVIN24

Thank you #SVIN24 for a wonderful fellows session today! Always great to connect with our future learners to showcase our current and new technologies! #JNJMedTech #stroke